MedTrace Logo

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

NCT05292443 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-02-23

No results posted yet for this study

Summary

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

Conditions

  • Primary Liver Cancer
  • Hepatocellular Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular-cholangiocarcinoma

Interventions

OTHER

Observation

observe the association of ctDNA with efficacy of treatment

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    collaborator OTHER

  • Geneplus-Beijing Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Feng Shen, MD PhD · Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2023-03-17
Completion
2023-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05292443 on ClinicalTrials.gov